Pill Pushers' Paperwork: FDA Seeks Input on Drug Distributor Checks
Published Date: 2/20/2026
Notice
Summary
The FDA wants your thoughts on how it collects info about groups that check and license drug wholesalers and delivery companies. This helps keep medicine safe and the supply chain strong. If you’re involved or interested, send your comments by April 21, 2026—no cost to join, just your voice!
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
Third Parties Can Drive Licenses
FDA will allow approved third-party organizations (AOs) to perform licensure reviews and inspections for wholesale drug distributors and third-party logistics providers (3PLs). FDA says it can rely on AO reports when deciding whether to issue a license under sections 583(c) and 584(d)(2)(A) of the FD&C Act.
Paperwork Burden Hours Estimated
FDA estimates the annual reporting burden as 15 respondents, 279 total responses, and 1,386 total hours. FDA also estimates recordkeeping as 18 recordkeepers, 102 total records, and 204 total hours per year for these collections under 21 CFR part 205.
7-Day AO Inspection Report Deadline
When an AO inspects a 3PL facility, the AO must provide FDA with an inspection report within 7 days after completion of the inspection. FDA will use the AO's report to make the final licensing decision for the facility.
AOs Must Keep Records Five Years
FDA proposes that an approved organization (AO) must maintain certain records for at least 5 years and make those records readily available to FDA upon request. This recordkeeping requirement applies as a condition of keeping AO approval.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11429 — Determination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that Protamine Sulfate and some other drugs weren’t taken off the market because they’re unsafe or don’t work. This means generic drug makers can keep getting approval to sell their versions, as long as they follow the rules. Patients and pharmacies can keep counting on these medicines without any interruptions or extra costs.
2026-11308 — Medical Devices; Orthopedic Devices; Classification of the Resorbable Calcium Salt Bone Void Filler Containing a Single Approved Aminoglycoside Antibacterial
The FDA is officially putting a special bone filler that slowly dissolves and fights bacteria into a safer, easier-to-manage category called Class II. This change helps make sure the product is safe and effective while speeding up patient access to this cool new tech. It’s been in effect since May 2022, so companies and patients can expect smoother approvals and fewer hoops to jump through.
2026-11302 — Medical Devices; Orthopedic Devices; Classification of the Absorbable Metallic Bone Fixation Fastener
The FDA is officially classifying absorbable metallic bone fixation fasteners as Class II devices with special safety rules, making them easier to get to patients while keeping them safe and effective. This change helps doctors and patients by reducing red tape and encouraging new, helpful bone-fixing tech. The new rules took effect on June 5, 2026, but have been in place since March 29, 2023, so manufacturers should already be on board.
2026-11306 — Medical Devices; Orthopedic Devices; Classification of the Shoulder Joint Humeral (Hemi-Shoulder) Ceramic Head/Metallic Stem Cemented or Uncemented Prosthesis
The FDA is officially putting the shoulder joint humeral ceramic head/metallic stem prosthesis into Class II, meaning it now has special safety rules but fewer red tape hurdles. This change helps patients get safer, innovative shoulder implants faster and makes life easier for makers by lowering regulatory costs. The new classification is effective June 5, 2026, but has been in effect since December 16, 2022.
2026-11303 — Intent To Exempt Certain Unclassified Medical Devices From Premarket Notification Requirements; Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA is planning to exempt some unclassified medical devices from the usual premarket notification rules, making it easier and faster for these devices to reach the market. This change affects manufacturers of certain medical devices and could save them time and money. The new guidance is effective starting June 5, 2026, but the FDA is still open to feedback from the public.
2026-11062 — Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
The FDA is officially pulling the plug on 16 generic drug approvals because the companies told them these medicines aren’t being sold anymore. This change kicks in on July 6, 2026, and it won’t stop companies from trying again later if they want. If you’re a drug maker or just curious, this means fewer old approvals cluttering the books and a cleaner, fresher drug list.
Previous / Next Documents
Previous: 2026-03332 — Agency Information Collection Activities; Proposed Collection; Comment Request; Hazard Analysis and Critical Control Point Procedures for the Safe and Sanitary Processing and Importing of Juice
The FDA wants to hear from juice makers and importers about their rules for keeping juice safe and clean using special safety checks called HACCP. They’re asking for comments by April 21, 2026, to help decide if they should keep or change these rules. This affects anyone who processes or imports fruit and vegetable juices and helps keep your juice safe without adding extra costs.
Next: 2026-03334 — Self-Regulatory Organizations; Cboe Exchange, Inc.; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Make a Number of Technical, Non-Substantive Changes to Its Rulebook
Cboe Exchange is updating its rulebook with a bunch of small, technical fixes that don’t change any big rules. These tweaks help keep everything clear and running smoothly for traders and the Exchange itself. The changes took effect right away on February 10, 2026, and won’t cost anyone extra or change how trading works.